Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study
暂无分享,去创建一个
S. Kusunoki | L. Benedetti | C. Briani | A. Echaniz-Laguna | E. Dardiotis | L. Visser | A. Lascano | O. Scheidegger | T. Kuntzer | E. Martinez-Hernandez | A. A. van der Eijk | S. Attarian | R. Huizinga | B. Jacobs | T. Harbo | C. Walgaard | A. J. van der Kooi | P. Ripellino | P. Tsouni | J. Samijn | C. Casasnovas | Samuel Arends | K. Jellema | S. Rinaldi | A. Y. Doets | S. Leonhard | K. Kuitwaard | Yuzhong Wang | P. Wirtz | M. Garssen | A. Humm | A. Vicino | F. Castellani | L. Appeltshauser | Linda W G Luijten | S. Arends | E. Martínez-Hernandez
[1] Benjamin Er,et al. Guillain‐Barré syndrome decreases in Singapore during the COVID‐19 pandemic , 2021, Journal of the peripheral nervous system : JPNS.
[2] Ò. Miró,et al. Incidence, clinical, risk factors and outcomes of Guillain‐Barré in Covid‐19 , 2020, Annals of Neurology.
[3] M. Filippi,et al. Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[4] I. Jahan,et al. Guillain‐Barré syndrome associated with SARS‐CoV‐2 infection: A systematic review and individual participant data meta‐analysis , 2020, Journal of the peripheral nervous system : JPNS.
[5] J. Vallat,et al. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[6] C. Selmi,et al. Guillain–Barré syndrome associated with SARS‐CoV‐2 infection. A systematic review , 2020, European journal of neurology.
[7] S. Farmer,et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome , 2020, medRxiv.
[8] Maria Thom,et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings , 2020, Brain : a journal of neurology.
[9] M. Koopmans,et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment , 2020, Nature Communications.
[10] B. Jacobs,et al. Guillain–Barré syndrome after SARS‐CoV‐2 infection , 2020, European journal of neurology.
[11] A. Flahault,et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.
[12] A. Lascano,et al. SARS‐CoV‐2 and Guillain–Barré syndrome: AIDP variant with a favourable outcome , 2020, European journal of neurology.
[13] G. Manousakis,et al. Neurological involvement of coronavirus disease 2019: a systematic review , 2020, Journal of Neurology.
[14] J. Sejvar,et al. Neurological associations of COVID-19 , 2020, The Lancet Neurology.
[15] F. Baldanti,et al. Guillain–Barré Syndrome Associated with SARS-CoV-2 , 2020, The New England journal of medicine.
[16] J. Benito-León,et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19 , 2020, Neurology.
[17] A. Amato,et al. COVID-19 and neuromuscular disorders , 2020, Neurology.
[18] L. Mao,et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.
[19] Dingding Shen,et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? , 2020, The Lancet Neurology.
[20] B. Jacobs,et al. Guillain-Barré syndrome related to Zika virus infection: A systematic review and meta-analysis of the clinical and electrophysiological phenotype , 2020, PLoS neglected tropical diseases.
[21] B. Song,et al. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review , 2020, European Radiology.
[22] J. Anaya,et al. Concurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika: A case report and review of the pathogenic role of multiple arboviral immunity , 2018, Journal of the Neurological Sciences.
[23] G. Marfia,et al. Regional variation of Guillain-Barré syndrome , 2018, Brain : a journal of neurology.
[24] J. Sejvar,et al. Guillain–Barré syndrome risk among individuals infected with Zika virus: a multi-country assessment , 2018, BMC Medicine.
[25] H. Endtz,et al. Guillain-Barré syndrome following varicella-zoster virus infection , 2018, European Journal of Clinical Microbiology & Infectious Diseases.
[26] H. Hartung,et al. International Guillain‐Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain‐Barré syndrome , 2017, Journal of the peripheral nervous system : JPNS.
[27] Xavier Deparis,et al. Zika Virus Seroprevalence, French Polynesia, 2014–2015 , 2017, Emerging infectious diseases.
[28] Jairo Lizarazo,et al. Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia. , 2016, The New England journal of medicine.
[29] Emmanuel Fournier,et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study , 2016, The Lancet.
[30] H. Dalton,et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection , 2014, Neurology.
[31] J. Sejvar,et al. Guillain-Barré Syndrome Following Influenza Vaccination: Causal or Coincidental? , 2011, Current infectious disease reports.
[32] R. Porcher,et al. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] J. Sejvar,et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. , 2011, Vaccine.
[34] E. Steyerberg,et al. A clinical prognostic scoring system for Guillain-Barré syndrome , 2007, The Lancet Neurology.
[35] J. Raphaël,et al. [Guillain-Barré syndrome]. , 2005, La Revue du praticien.
[36] H. Hartung,et al. Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome , 1998, Annals of neurology.
[37] L. Visser,et al. Campylobacter jejuni infections and anti‐GM1 antibodies in guillain‐barré syndrome , 1996, Annals of neurology.
[38] J A Bryan,et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. , 1979, American journal of epidemiology.
[39] R. Hughes,et al. CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.
[40] R. Evans. European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[41] A. Kumar,et al. Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients , 2009 .
[42] D. Cornblath,et al. Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.